Femasys Inc. - Common Stock (FEMY)

ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement.

-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) --

-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain --

Femasys continues to expand access and market share for its first-line infertility treatment option

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.

-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® --

First-in-world approval of FemBloc delivery system for women seeking permanent birth control

--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--

UK regulatory approval follows FemaSeed, FemVue and FemCerv clearance/ approvals in the U.S., Europe, Canada and Israel

Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024

European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution

HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California

Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients

Company accelerated commercialization with significant new partnerships both in the U.S. and Europe

Premier conference focused on gynecological surgery

FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control

Boston IVF to begin providing FemaSeed as an infertility treatment option to expand access for patients across nearly 30 centers nationwide

Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council

ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment

Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial